AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sim1 who wrote (42)	5/22/2001 5:11:30 PM
From: keokalani'nui	Read Replies (1) of 332

Thank you Stuart. I think that idiotic news report (about failing phase III!) had 0 to do with the market response. Here's the good news, as I read it: If you like probucol and would really like a side-effect-free probucol (and you can confirm with Tardiff (sp.) that there was a therapeutic benefit 10 minutes after stenting/probucol), you should be elated. Here's what I don't get: How in the world can there be a drug benefit that accounts for the bulk (or quite a large portion) of the increased lumin diameter within 10 MINUTES of the procedure? And why is it apparently the partner carrying the money that is recalcitrant in pronouncing success? Plus, a one-dose pre-procedure doesn't look like the same market size as continuous treatment 6 months post. On the other hand, I recognize that all drug arms showed SS improvement in lumin size at 6 months vs. placebo, so it looks like it's not the procedure that accounts for the improvement. I thought restenosis was marked by a gradual reclosing. Still needing an expert here. Chance for riches. Come on........ Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next